Zynex (ZYXI) Stock Price, News & Analysis

Company Overview

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Key Stats

• Today's Range: $2.20 to $2.43
• 50-Day Range: $1.66 to $2.59
• 52-Week Range: $1.66 to $10.62
• Volume: 453,880 shs
• Average Volume: 162,620 shs
• Market Capitalization: $69.25 million
• P/E Ratio: 15.27
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

Zynex Stock Analysis - MarketRank™

Zynex scored higher than 55% of companies evaluated by MarketBeat, and ranked 489th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Zynex has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Zynex has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 135.00%

Earnings Growth

Earnings for Zynex are expected to grow by 135.00% in the coming year, from $0.20 to $0.47 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zynex is 15.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.23.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zynex is 15.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.88.

Price to Book Value per Share Ratio

Zynex has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.95% of the float of Zynex has been sold short.

Short Interest Ratio / Days to Cover

Zynex has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.

Change versus previous month

Short interest in Zynex has recently increased by 3.17%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zynex does not currently pay a dividend.

Dividend Growth

Zynex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

21.95% of the float of Zynex has been sold short.

Short Interest Ratio / Days to Cover

Zynex has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.

Change versus previous month

Short interest in Zynex has recently increased by 3.17%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.62

News Sentiment

Zynex has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Zynex this week, compared to 7 articles on an average week.

MarketBeat Follows

Only 1 people have added Zynex to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Zynex insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $71,500.00 in company stock.

Percentage Held by Insiders

49.28% of the stock of Zynex is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 29.68% of the stock of Zynex is held by institutions.

ZYXI Stock Analysis - Frequently Asked Questions

How have ZYXI shares performed this year?

Zynex's stock was trading at $8.01 at the beginning of 2025. Since then, ZYXI stock has decreased by 71.4% and is now trading at $2.29.
View the best growth stocks for 2025 here.

How were Zynex's earnings last quarter?

Zynex, Inc. (NASDAQ:ZYXI) issued its quarterly earnings data on Monday, April, 28th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.09. The company had revenue of $26.58 million for the quarter, compared to the consensus estimate of $30.83 million. Zynex had a trailing twelve-month return on equity of 13.05% and a net margin of 2.49%.
Read the conference call transcript.

Who are Zynex's major shareholders?

Zynex's top institutional shareholders include Goldman Sachs Group Inc. (0.56%), Bank of New York Mellon Corp (0.53%), Janney Montgomery Scott LLC (0.49%) and Jane Street Group LLC (0.18%). Insiders that own company stock include Thomas Sandgaard, Joshua R Disbrow, Anna Lucsok and Daniel J Moorhead.
View institutional ownership trends.

How do I buy shares of Zynex?

Shares of ZYXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zynex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zynex investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY) and Humana (HUM).

Company Calendar

• Last Earnings: 4/28/2025
• Today: 5/31/2025
• Next Earnings (Estimated): 7/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:ZYXI
• CIK: 846475
• Web: www.zynex.com
• Phone: (303) 703-4906
• Fax: N/A
• Employees: 770
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.00
• High Stock Price Target: $8.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +162.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.24)
• Trailing P/E Ratio: 15.27
• Forward P/E Ratio: 11.45
• P/E Growth: N/A
• Net Income: $9.73 million
• Net Margins: 2.49%
• Pretax Margin: 3.48%
• Return on Equity: 13.05%
• Return on Assets: 3.78%

Debt

• Debt-to-Equity Ratio: 1.66
• Current Ratio: 3.94
• Quick Ratio: 3.15

Sales & Book Value

• Annual Sales: $172.40 million
• Price / Sales: 0.40
• Cash Flow: $0.13 per share
• Price / Cash Flow: 18.01
• Book Value: $1.36 per share
• Price / Book: 1.68

Miscellaneous

• Outstanding Shares: 30,239,000
• Free Float: 15,245,000
• Market Cap: $69.25 million
• Optionable: Optionable
• Beta: 0.70